Ibions Seeks Investors and Anticipates Revenue of €1.5 Million in 3 Years

Ibions is looking for capital to grow. The Alicante startup, which has developed a platform that provides assistance to cancer patients, has opened a first round of investment of €250,000 to boost its growth throughout the state, according to Julio Madrigall, co-founder of the group.

The company, founded in 2022, plans to reach its first income this year, with a turnover of €35,000, which will increase to €200,000 in 2024, €600,000 in 2025, and will grow to €1.5 million in 2026, if the company’s route sheet is met.

Ibions is developing a medical platform to accompany cancer patients. Through a team of medical professionals, the company offers follow-up on the nutrition of patients, creates a road map with physical exercises, and provides psychological support to patients.

Read more about Ibions and its medical platform with our companion app. The Born2Invest mobile app brings you the most important financial news of the day so you can stay informed.

Ibions is developing its first pilot tests in Spanish private hospitals

The objective of this first round of investment is to complete the development of the platform through which the company will provide services, with special attention to the implementation of Artificial Intelligence (AI) in the app. Added to the money raised is a grant of €40,000 from Activa Startup, which Ibions will allocate to carrying out clinical trials that will allow it to demonstrate the efficacy of its treatment.

The company has already contacted various public hospitals in search of collaboration while developing its first pilots in private medical centers, “because access is easier,” Madrigall stresses. Ibions has already presented his project at GenesisCare, Vithas, and is in talks with Ivo and Imed.

Once it expands through the state market, the group will want to make the leap to Latin America, where it identifies a market close to Spanish “because of language facilities.” After disembarking on the other side of the ocean, he will return to the Old Continent and try to land in his last objective: the United States.

The company plans to jump to Latin America once it is consolidated in the state market

The company entered Lanzadera in September 2022, which, according to Madrigall, “was a before and after in terms of accompaniment and mentoring in finance, entrepreneurship, and innovation.”

Currently, Ibions already has a network of fifty patients. The service offered by the company lasts for three months and eight online sessions, with medical, psychological, and nutritional support. The price of the service amounts to €450 per month.

“One of the entry doors that we observed was the possibility of educating the patient and their caregiver, who have many doubts about almost everything at that time,” says Madrigall, who concludes that in cancer care there is a great deficiency in the incorporation of therapeutic nutrition, psychological support, and physical exercise.

__

(Featured image by armennano via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.